

DAFTAR PUSTAKA

1. Hui DS, I Azhar E, Madani TA, et al. The Continuing 2019 n-CoV epidemic threat of novel coronaviruses to global heallth - The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis* 2020; 91:264-266.
2. Handayani D, Hadi D, Isbaniah F, et al. Penyakit Virus Corona 2019. *J Respirologi Indonesia*. 2020;40:119-129.
3. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020;395:565-574.
4. World Health Organization. Number et a Glance. WHO International 2022. Buku 2022.
5. Kementrian Kesehatan Republik Indonesia. Dashboard Data Kasus COVID-19 di Indonesia. Kemenkes RI. 2022.
6. Deng G, Yin M, Chen X, Zeng F, et al. Clinical determinants for fatality of 44,672 patients with COVID-19. *Crit Care*. 2020;24:1-3.
7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.
8. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Whuan, China. *JAMA – J Am Med Assoc*. 2020;323:1061-1069.
9. Khan S, Tombologlu H, Hassanein SE, et al. Coronavirus dieases 2019: Current biological situation and potential therapeutic perspective. *Eur J Pharmacol*. 2020;886:1-8.
10. Wiersinga WJ, Rhodes A, Cheng AC, et al. Phatophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Deases 2019 (COVID-19): A Review. *JAMA-J Am Med Assoc*. 2020;324:782-793.

11. Bouruiba L. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19. *JAMA*. 2020 May 12;323;1837-1838.
12. Lewis D. Is the coronavirus airborne? Experts can't agree. *Nature*. 2020 Apr;580:175.
13. Susilo A, Rumende MC, Pitoyo CW, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini Coronavirus Disease 2019: Review of Current Literatures. 2020;7:45-67.
14. Burhan E, Susanto AD, Nasution SA, et al. Pedoman tatalaksana COVID-19. 2020:1-38.
15. South AM, Brady TM, Flynn JT et al. ACE 2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use during the pandemic: The Pediatric Perspective. *Hypertension*. 2020;76:16-22.
16. Verdecchia P, Cavallini C, Spanecello A, et al. COVID-19: ACE2centric Infective Disease? *Hypertension*. 2020;294-299.
17. Srivastava P, Badhwar S, Chandran DS, et al. Imbalance between Angiotensin II-Angiotensin (1-7)system is associated with vascular endothelial dysfunction and inflammation in type 2 diabetes with newly diagnosed hypertension. *Diabetes Metab Syndr Clin Res Rev*. 2019;13:1-22.
18. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol*. 2020;109:1-8.
19. Petrie JR, Guzik TJ, Touyz RM. Diabetes Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. *Can J Cardiol*. 2018;34:575-584.
20. Moutschen M, Scheen A, Lefebvre P. Impaired immune responses in diabetic mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. *Diabetes Metab*. 1992;18:187-201.

21. Leung JM, Niikura M, Yang CWT, et al. COVID-19 and COPD. *Eur Respir J*. 2020;56:1-9.
22. Leung JM, Yang CX, Sin DD. Early View Correspondence COVID-19 and Nicotine as a Mediator of ACE-2. *Eur Respir J*. 2020;55:1-4.
23. Minakata Y, Nakanishi M, Hirano T, et al. Microvascular hypermeability in COPD airways. *Thorax*. 2005;60:882-883.
24. Liu C, Jiang Z, Shao C, et al. Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study. *Zhonghua Gan Zang Bing Za Zhi*. 2020;28:148-152.
25. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol*. 2020;21:335-337.
26. Addeo a, Obeid M, Friedlaender A. COVID-19 and lung cancer. Risks, mechanisms and treatment interactions. *J Immunother Cancer*. 2020:1-7.
27. Sattar N, McInnes IB, McMurray, et al. Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. *Circulation*. 2020;142:4-6.
28. Chmielwska B, Barrat I, Townsend R, et al. Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. *Lancet Glob Heal*. 2021;9:759-772.
29. Arthurs AL, Jankovic KT, Robbert CT. COVID-19 in pregnancy: What we know from the first year of the pandemic. *Biochim Biophys Acta-Mol Basis Dis*. 2021;1867.
30. Masturoh I, Tamesvari NA. *Bahan Ajar Rekam Medis dan Informasi Kesehatan: Metodologi Penelitian Kesehatan*. Jakarta: Kementrian Kesehatan Republik Indonesia; 2018.
31. Sastroasmoro S. *Dasar-Dasar Metodologi Penelitian Klinis*. Jakarta: Sagung Seto; 2014.
32. Leong R, Lee TSJ, Chen Z, et al. Global Temporal Patterns of Age Group and Sex Distributions of COVID-19. *Infect Dis Rep*. 2021;13:582-596.

33. Stywan DA. Pandemi COVID-19 dalam perspektif Demografi. Seminar Nasional Official Statistics; 2020;182-189.
34. Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. *Nat Commun.* 2020;11:6317.
35. Centers for Disease Control and Prevention. Risk for COVID-19 Infection, Hospitalization, and Death By Age Group. CDC Web Page. 2021.
36. Putri NA, Putri AE, Mariko R. Hubungan Usia, Jenis Kelamin, dan Gejala dengan Kejadian COVID-19 di Sumatera Barat. *Majalah Kedokteran Andalas.* 2021;44:104-111.
37. Biswas M, Rahamana S, Biswas TK, et al. Association of Sex, Age and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirology.* 2021;64:36-47.
38. Widjaja JT, Kwee L, Giantara AK, Subagiyo HA, Edwin C, Putri RL. Karakteristik Pasien COVID-19 Rawat Inap di RS Immanuel Bandung Indonesia. *Journal of Medicine Health.*
39. Karya KWS, Suwidnya IM, Wijaya BS. Hubungan Penyakit Komorbiditas terhadap Derajat Klinis COVID-19. *Intisari Sains Medis.* 2021;12:708-717.
40. Ellington S, Strid P et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status-United States, January 22-June 7, 2020. *MMWR.* 2020;69:769-775.
41. Alkautsar A. Hubungan Penyakit Komorbid dengan Tingkat Keparahan Pasien COVID-19. *Jurnal Medika Utama.* 2021;3:1488-1494.
42. Gosain R, Abdou Y, Singh A, et al. COVID-19 and Cancer: a Comprehensive Review. *Curr Oncol Rep.* 2020;22:53.
43. Martinez MA, Franco S. Impact of COVID-19 in Liver Disease Progression. *Hepatol Commun.* 2021;5:1138-1150.
44. Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J.* 2020;55.

45. Herbawani C K, Cukarso S N, Maulana I M, et al. Dampak COVID-19 pada Kesehatan Ibu hamil: literatur review. 2020;2:76-85.
46. Eman S. Wabah Corona Virus Disease COVID-19 dalam Pandangan Islam. Salam. 2020;7:555-564.
47. Mahmudin H. Rukhsah (Keringanan) bagi Orang Sakit dalam Perspektif Islam. Jurnal Ilmiah Al-Qalam. 2017;11:65-85.
48. Ya'cub. Peran Pendidikan Islam dalam Menghadapi Ujian COVID-19 (Studi Krisis Adanya Pandemi COVID-19). Cendekia. 2020;6:114-132.
49. Setiadi O. Kematian dalam Perspektif Islam. Jurnal Al-Ashriyyah. 2017;4:69-93.
50. Moh. Badrudin. Ilmu Ushul Fiqih; 2019.
51. Sarwat A. Maqashid Syariah. 2019 April 9; 4-62.